Home » Stocks » PULM

Pulmatrix, Inc. (PULM)

Stock Price: $0.845 USD -0.009 (-1.09%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $0.850 +0.005 (0.58%) Jul 30, 4:46 PM
Market Cap 47.52M
Revenue (ttm) 11.26M
Net Income (ttm) -18.73M
Shares Out 46.03M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $0.845
Previous Close $0.854
Change ($) -0.009
Change (%) -1.09%
Day's Open 0.843
Day's Range 0.830 - 0.854
Day's Volume 241,345
52-Week Range 0.820 - 3.040

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

LEXINGTON, Mass., July 27, 2021 /PRNewswire/ --  Pulmatrix, Inc.  (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...

5 days ago - PRNewsWire

LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...

2 months ago - PRNewsWire

LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

3 months ago - PRNewsWire

LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Pr...

3 months ago - PRNewsWire

LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

3 months ago - PRNewsWire

LEXINGTON, Mass., March 23, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

4 months ago - PRNewsWire

LEXINGTON, Mass., March 4, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...

4 months ago - PRNewsWire

LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...

5 months ago - PRNewsWire

LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary...

10 months ago - PRNewsWire

LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc.

11 months ago - PRNewsWire

Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

LEXINGTON, Mass., June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary ...

1 year ago - PRNewsWire

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

Other stocks mentioned: CODX, JNJ, TRIL, VXRT
1 year ago - Zacks Investment Research

Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet" with Cipla Ltd.

2 years ago - Market Watch

About PULM

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trial... [Read more...]

Industry
Biotechnology
Founded
2003
CEO
Teofilo Raad
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
PULM
Full Company Profile

Financial Performance

In 2020, Pulmatrix's revenue was $12.63 million, an increase of 59.72% compared to the previous year's $7.91 million. Losses were -$19.31 million, -6.25% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Pulmatrix stock is "Buy" and the 12-month stock price forecast is 5.00.

Price Target
$5.00
Analyst Consensus: Buy